Two-Drug Combination Produced Strong Results In Late Stage Ovarian Cancer Phase II Trial

Researchers were surprised that late stage ovarian cancer patients responded well to an experimental carboplatin-decitabine combination therapy, given that they had become resistant to carboplatin. Indiana University researchers are eager to conduct a larger human study to test the two-drug combination with existing treatment for ovarian cancer. The carboplatin-decitabine combo had a positive effect on 70% of the trial participants. The researchers added that they believe they have discovered biomarkers which could help better identify patients who are most likely to respond to this therapy...

doctor oz